

Consent for Pfizer-BioNTech COVID-19 Vaccines Ages 5-11 (Orange Cap 0.2mL Dose)

Minor Last Name:		First Name:			<u>M.I.</u>
Minor DOB:	Age:	Weight:		Gender	r: M/F
Parent/Guardian Last Name:		First Name:			
Relationship to patient:	Parent/Guardian Phone Number:				
Minor's Primary Care Provid	Phone Number (if not WHC):				
I have received and read the V ABOUT THE PFIZER-BIONTECH FOR USE IN INDIVIDUALS 5 TH consent for my child to receive regarding the Hawaii Immuniz I affirm that I am the parent of	COVID-19 VACCINE ROUGH 11 YEARS OF the Pfizer COVID-19 ation Registry (see a	TO PREVENT COF AGE. I understa 9 vaccine. In addi ttached).	ONAVIRUS D nd the risks a tion, I have re	ISEASE 2019 and benefits a eceived infor	(COVID-19) and give
Parent/Guardian Signature:			Date:		
For vaccine recipients:					
For vaccine recipients: The following questions will he vaccine today.	elp us determine if tl	nere is any reasoi	n you should r	not get the C	OVID-19
The following questions will he	estions, it does not n	ecessarily mean y	ou should no	t be vaccina	ted. It just
The following questions will he vaccine today. If you answer "yes" to any que means additional questions m	estions, it does not n ay be asked. If a que	ecessarily mean y estion is not clear	ou should no	t be vaccina	ted. It just



Consent for Pfizer-BioNTech COVID-19 Vaccines Ages 5-11 (Orange Cap 0.2mL Dose)

1.	Have you ever received a dose of Pfizer COVID-19 vaccine? a. If yes, Where? b. Date of dose 1 c. Date of dose 2 d. Did you bring your vaccination record card or other documentation? Yes No Pfizer booster approved for ages 12+. Moderna booster approved for ages 18+.	Yes	No	Don't know
2.	Do you have a health condition or are you undergoing treatment that makes you moderately or severely immunocompromised? (This would include treatment for cancer or HIV, receipt of organ transplant, immunosuppressive therapy or high-dose corticosteroids, CAR-T-cell therapy, hematopoietic cell transplant (HCT), DiGeorge syndrome or Wiskott-Aldrich syndrome) A Third Dose of Pfizer is for children ages 5-11 with moderately to severely compromised immune systems that can be administered at least 28 days after the second dose of Pfizer. Please note this is different than a booster dose.	Yes	No	Don't Know
3.	Have you ever had an allergic reaction to (see list below (This would include a severe allergic reaction (e.g., anaphylax with epinephrine or EpiPen or that caused you to go to the hor reaction that occurred within 4 hours that caused hives, swell wheezing.) If yes to any of the below, STOP and do not proceed. Vaccine a. A component of the COVID-19 vaccine, including polyethylene glycol (PEG), which is found in some medications, such as laxatives and preparations for colonoscopy procedures b. Polysorbate, which is found in some vaccines, film coated tablets, and intravenous steroids c. A previous dose of COVID-19 vaccine	is) that requir ospital. It woo ling, or respira	uld also includ atory distress	le an allergic
4.	Have you ever had an allergic reaction to another vaccine (other than COVID-19 vaccine) or an injectable medication? (This would include a severe allergic reaction (e.g. anaphylaxis) that required treatment with epinephrine or EpiPen or that caused you to go to the hospital. It would also	Yes	No	Don't know



Consent for Pfizer-BioNTech COVID-19 Vaccines Ages 5-11 (Orange Cap 0.2mL Dose)

	include an allergic rection that occurred within 4 hours that caused hives, swelling, or respiratory distress, including wheezing.			
	If yes, inform patient he/she will be observed for 30 minutes after vaccination. If patient has questions, should be referred to Provider.			
	*RN: counsel patients about unknown risks vs benefits of vaccination, refer patient to Provider if further discussion needed. Observe for 30 mins after vaccination.			
5.	Diagnosed with Multisystem Inflammatory Syndrome (MIS-C or MIS-A) after a COVID-19 infection? If yes, should refer patient to Provider prior to scheduling. Consider delaying vaccine until recovery from infection and 90 days after date of diagnosis.	Yes	No	Don't know
6.	Have a history of myocarditis or pericarditis? If yes, should refer patient to Provider. People who develop myocarditis or pericarditis after a first dose of an mRNA COVID-19 vaccine should defer receiving the second dose.	Yes	No	Don't know
	If patient has a history of myocarditis or pericarditis unrelated to mRNA COVID-19 vaccination, may receive any FDA-authorized COVID-19 vaccine after episode has completely resolved.			
7.	Check all that apply to you:		-	
	 Had a severe allergic reaction to something other 			
	than a vaccine or injectable therapy such as food,			
	pet, venom, environmental or oral medication			
	allergies (30 min observation)			
	□ Take immunosuppressive drugs or therapies			
	□ Have a bleeding disorder			
	□ Take a blood thinner			
	Have a history of heparin-induced			
	thrombocytopenia(HIT) History of Guillain-Barre Syndrome (GBS)			
For Office	e Use Only:			
Date/tim	e given:			
From rev	iewed/Administered by: Observed for 15 minute	s/30 minute	es. Pt Initial	s:
Pfizer Or	ange Cap Vaccine 0.2mL Dose: 1 2 3 Si	te: RD	LD	
Vaccine I	Name/Lot #/Expiration/Dose/Route: *Place Sticker Here			